Back to Journals » Therapeutics and Clinical Risk Management » Volume 15

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

Total article views   HTML views PDF downloads Totals
14,496 Dovepress* 8,482+ 2,151 10,633
PubMed Central* 6,014 646 6,660
Totals 14,496 2,797 17,293
*Since 31 January 2019
Total mentioned Facebook Delicious Reddit Twitter Others
2 1 0 0 0 1

View citations on PubMed Central and Google Scholar